Table 2 Prevalence of BRCA1-like phenotype in the large-scale breast cancer cohorts, TCGA and METABRIC
| Â | TCGA | METABRIC | ||||
|---|---|---|---|---|---|---|
BRCA1-like | non-BRCA1-like | P value § | BRCA1-like | non-BRCA1-like | P value § | |
n | 308 | 649 | Â | 343 | 1625 | Â |
Age, years (mean (sd)) | 56.57 (13.26) | 59.33 (13.06) | 0.002 | 56.74 (13.93) | 62.02 (12.56) | < 0.001 |
Stage (%) | Â | Â | 0.22 | Â | Â | 0.35 |
 Stage I-II | 238 (77.3) | 473 (72.9) |  | 220 (64.1) | 1106 (68.1) |  |
 Stage III-IV | 63 (20.5) | 165 (25.4) |  | 26 (7.6) | 102 (6.3) |  |
 (Missing) | 7 (2.3) | 11 (1.7) |  | 97 (28.3) | 417 (25.7) |  |
ER (%) | Â | Â | < 0.001 | Â | Â | < 0.001 |
 Positive | 129 (41.9) | 575 (88.6) |  | 108 (31.5) | 1393 (85.7) |  |
 Negative | 166 (53.9) | 43 (6.6) |  | 235 (68.5) | 232 (14.3) |  |
 (Missing) | 13 (4.2) | 31 (4.8) |  | 0 (0.0) | 0 (0.0) |  |
PR (%) | Â | Â | < 0.001 | Â | Â | < 0.001 |
 Positive | 97 (31.5) | 514 (79.2) |  | 57 (16.6) | 980 (60.3) |  |
 Negative | 195 (63.3) | 104 (16.0) |  | 286 (83.4) | 645 (39.7) |  |
 NA | 16 (5.2) | 31 (4.8) |  | 0 (0.0) | 0 (0.0) |  |
HER2 (%) | Â | Â | 0.59 | Â | Â | 0.98 |
 Positive | 50 (16.2) | 93 (14.3) |  | 43 (12.5) | 200 (12.3) |  |
 Negative | 161 (52.3) | 333 (51.3) |  | 300 (87.5) | 1425 (87.7) |  |
 (Missing) | 97 (31.5) | 223 (34.4) |  | 0 (0.0) | 0 (0.0) |  |
Any ER, PR, or HER2 positivity (%) | Â | Â | < 0.001 | Â | Â | < 0.001 |
 Yes | 159 (51.6) | 595 (91.7) |  | 143 (41.7) | 1508 (92.8) |  |
 No | 88 (28.6) | 12 (1.8) |  | 200 (58.3) | 117 (7.2) |  |
 Cannot be determined | 61 (19.8) | 42 (6.5) |  | 0 (0.0) | 0 (0.0) |  |